Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ARDX NASDAQ:BCAX NASDAQ:IMCR NASDAQ:LXEO On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeARDXArdelyx$6.05$6.11$3.49▼$8.40$1.49B0.582.83 million shs9.84 million shsBCAXBicara Therapeutics$23.23$21.79$8.48▼$24.25$1.53B-0.53472,089 shs1.93 million shsIMCRImmunocore$28.60$29.38$27.56▼$40.71$1.45B0.74433,075 shs812,334 shsLXEOLexeo Therapeutics$4.93$5.43$3.60▼$10.99$387.10M1.38699,211 shs1.48 million shs(Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceARDXArdelyx+3.60%+4.49%-0.66%+13.94%+67.59%BCAXBicara Therapeutics+1.35%+9.16%+15.98%+26.18%+146.34%IMCRImmunocore+0.18%-0.07%-1.14%-4.38%-9.78%LXEOLexeo Therapeutics-1.00%+17.38%+10.04%-12.74%+16.27%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeARDXArdelyx$6.05$6.11$3.49▼$8.40$1.49B0.582.83 million shs9.84 million shsBCAXBicara Therapeutics$23.23$21.79$8.48▼$24.25$1.53B-0.53472,089 shs1.93 million shsIMCRImmunocore$28.60$29.38$27.56▼$40.71$1.45B0.74433,075 shs812,334 shsLXEOLexeo Therapeutics$4.93$5.43$3.60▼$10.99$387.10M1.38699,211 shs1.48 million shs(Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceARDXArdelyx+3.60%+4.49%-0.66%+13.94%+67.59%BCAXBicara Therapeutics+1.35%+9.16%+15.98%+26.18%+146.34%IMCRImmunocore+0.18%-0.07%-1.14%-4.38%-9.78%LXEOLexeo Therapeutics-1.00%+17.38%+10.04%-12.74%+16.27%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceARDXArdelyx 2.91Moderate Buy$15.73159.95% UpsideBCAXBicara Therapeutics 2.73Moderate Buy$30.2730.32% UpsideIMCRImmunocore 2.56Moderate Buy$56.7198.30% UpsideLXEOLexeo Therapeutics 2.88Moderate Buy$20.14308.58% UpsideCurrent Analyst Ratings BreakdownLatest LXEO, BCAX, IMCR, and ARDX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/16/2026ARDXArdelyx LADENBURG THALM/SH SHSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$16.006/11/2026LXEOLexeo Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)5/29/2026LXEOLexeo Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)5/27/2026BCAXBicara Therapeutics Cantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOverweight5/15/2026LXEOLexeo Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)5/12/2026BCAXBicara Therapeutics Morgan StanleySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$36.00 ➝ $37.005/12/2026BCAXBicara Therapeutics The Goldman Sachs GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetNeutral$16.00 ➝ $18.005/11/2026BCAXBicara Therapeutics GuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$42.005/11/2026LXEOLexeo Therapeutics Chardan CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$17.005/10/2026BCAXBicara Therapeutics GuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy5/7/2026IMCRImmunocore Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong Sell ➝ Strong-Buy(Data available from 6/19/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookARDXArdelyx$407.32M3.67N/AN/A$0.69 per share8.77BCAXBicara TherapeuticsN/AN/AN/AN/A$7.33 per shareN/AIMCRImmunocore$400.02M3.64N/AN/A$7.52 per share3.80LXEOLexeo TherapeuticsN/AN/AN/AN/A$3.38 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateARDXArdelyx-$61.60M-$0.23N/A10.80N/A-13.58%-38.11%-11.85%8/3/2026 (Estimated)BCAXBicara Therapeutics-$137.95M-$2.78N/AN/AN/AN/A-35.89%-33.78%8/11/2026 (Estimated)IMCRImmunocore-$35.51M-$0.55N/A32.87N/A-6.68%-7.07%-2.55%8/6/2026 (Estimated)LXEOLexeo Therapeutics-$99.96M-$1.45N/AN/AN/AN/A-47.48%-41.72%8/13/2026 (Estimated)Latest LXEO, BCAX, IMCR, and ARDX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/11/2026Q1 2026BCAXBicara Therapeutics-$0.72-$0.93-$0.21-$0.93N/AN/A5/11/2026Q1 2026LXEOLexeo Therapeutics-$0.29-$0.25+$0.04-$0.25N/AN/A5/6/2026Q1 2026IMCRImmunocore-$0.26$0.25+$0.51$0.25$145.20 million$106.68 million4/30/2026Q1 2026ARDXArdelyx-$0.13-$0.15-$0.02-$0.15$92.78 million$94.47 million3/30/2026Q4 2025BCAXBicara Therapeutics-$0.72-$0.68+$0.04-$0.68N/AN/A3/30/2026Q4 2025LXEOLexeo Therapeutics-$0.32-$0.27+$0.05-$0.27N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthARDXArdelyxN/AN/AN/AN/AN/ABCAXBicara TherapeuticsN/AN/AN/AN/AN/AIMCRImmunocoreN/AN/AN/AN/AN/ALXEOLexeo TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioARDXArdelyx1.373.493.28BCAXBicara TherapeuticsN/A13.8513.85IMCRImmunocore1.004.184.15LXEOLexeo TherapeuticsN/A14.1614.16Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipARDXArdelyx58.92%BCAXBicara TherapeuticsN/AIMCRImmunocore84.50%LXEOLexeo Therapeutics60.67%Insider OwnershipCompanyInsider OwnershipARDXArdelyx5.30%BCAXBicara Therapeutics13.80%IMCRImmunocore10.10%LXEOLexeo Therapeutics2.00%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableARDXArdelyx90247.03 million233.94 millionOptionableBCAXBicara Therapeutics3265.70 million56.64 millionN/AIMCRImmunocore32050.87 million45.73 millionOptionableLXEOLexeo Therapeutics5878.52 million76.95 millionNot OptionableLXEO, BCAX, IMCR, and ARDX HeadlinesRecent News About These CompaniesLexeo Therapeutics Announces Publication in JAMA Cardiology of Phase I/II Data for LX2006 in Friedreich AtaxiaJune 17 at 4:01 PM | globenewswire.comLexeo Therapeutics, Inc. (LXEO) Shareholder/Analyst Call TranscriptJune 15, 2026 | seekingalpha.comWhy Is Lexeo Therapeutics Stock Gaining Monday?June 15, 2026 | benzinga.comLexeo Therapeutics Advances SUNRISE-FA 2 Pivotal Trial for Gene Therapy LX2006 in Friedreich Ataxia CardiomyopathyJune 15, 2026 | quiverquant.comQLexeo Therapeutics Announces Regulatory Update and Registrational Trial Design for LX2006 Gene Therapy in Friedreich AtaxiaJune 15, 2026 | globenewswire.comLexeo Therapeutics (NASDAQ:LXEO) CEO Sells $16,910.52 in StockMay 21, 2026 | insidertrades.comLexeo Therapeutics to Participate in the 2026 RBC Capital Markets Global Healthcare ConferenceMay 19, 2026 | globenewswire.comLXEO Share News TodayMay 16, 2026 | uk.investing.comLexeo Highlights Q1 Progress Advancing Cardiac Gene TherapiesMay 11, 2026 | tipranks.comLexeo Therapeutics Reports First Quarter 2026 Financial Results and Operational HighlightsMay 11, 2026 | globenewswire.comLexeo Therapeutics Adds Genomic Medicine Leader to BoardApril 30, 2026 | tipranks.comLexeo Therapeutics to Present New Cardiac Gene Therapy Data at ASGCT Annual Meeting 2026April 27, 2026 | quiverquant.comQLexeo Therapeutics Announces Multiple Presentations at the 29th American Society of Gene & Cell Therapy (ASGCT) Annual MeetingApril 27, 2026 | markets.businessinsider.comLexeo Therapeutics Announces Multiple Presentations at the 29th American Society of Gene & Cell Therapy (ASGCT) Annual MeetingApril 27, 2026 | globenewswire.comLexeo Therapeutics (NASDAQ:LXEO) CEO Sells $312,950.00 in StockApril 8, 2026 | insidertrades.comWill Lexeo Therapeutics (NASDAQ:LXEO) Spend Its Cash Wisely?April 1, 2026 | finance.yahoo.comLexeo Therapeutics Advances Cardiac Gene Therapies, Strengthens FinancesMarch 30, 2026 | tipranks.comLexeo Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Operational HighlightsMarch 30, 2026 | globenewswire.comLexeo Therapeutics to Participate in the Leerink Global Healthcare ConferenceMarch 3, 2026 | globenewswire.comLexeo Therapeutics (NASDAQ:LXEO) COO Jose Manuel Otero Sells 3,016 SharesFebruary 21, 2026 | insidertrades.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeLXEO, BCAX, IMCR, and ARDX Company DescriptionsArdelyx NASDAQ:ARDX$6.05 0.00 (0.00%) Closing price 06/18/2026 04:00 PM EasternExtended Trading$6.06 +0.01 (+0.17%) As of 06/18/2026 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Ardelyx, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally. The company's lead product candidate is tenapanor for the treatment of patients with irritable bowel syndrome with constipation. It also develops XPHOZAH, which is in Phase III clinical trial to reduce serum phosphorus in adults with chronic kidney disease (CKD)on dialysis, or hyperphosphatemia; RDX013, a potassium secretagogue, for the treatment of elevated serum potassium, or hyperkalemia, a problem among patients with kidney and/or heart failure; and RDX020, for adult patients with metabolic acidosis, a serious electrolyte disorder. The company has agreements with Kyowa Kirin, Fosun Pharmaceutical Industrial Development Co. Ltd., and Knight Therapeutics, Inc. for the development and commercialization of tenapanor in their respective territories. The company was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in June 2008. Ardelyx, Inc. was incorporated in 2007 and is headquartered in Waltham, Massachusetts.Bicara Therapeutics NASDAQ:BCAX$23.23 0.00 (0.00%) Closing price 06/18/2026 04:00 PM EasternExtended Trading$23.24 +0.02 (+0.06%) As of 06/18/2026 04:38 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Bicara Therapeutics Inc., a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b) for the treatment of solid tumors. The company was incorporated in 2018 and is based in Boston, Massachusetts.Immunocore NASDAQ:IMCR$28.60 0.00 (0.00%) Closing price 06/18/2026 04:00 PM EasternExtended Trading$28.58 -0.02 (-0.07%) As of 06/18/2026 05:27 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma. In addition, the company's product pipeline comprises IMC-F106C, which is in a Phase 3 clinical trial to treat first line advanced cutaneous melanoma; and in a Phase 1/2 clinical trial in multiple tumor types, such as platinum resistant ovarian, non-small cell lung, and endometrial carcinoma. Further, it develops IMC-R117C, which is in phase 1 clinical trial to treat colorectal and gastrointestinal cancers; IMC-M113V, which is in phase 1 clinical trial to treat human immunosuppression virus; IMC-I109V, which is in a Phase I clinical trial in patients with chronic hepatitis B virus; IMC-T119C, which is in preclinical trial for multiple solid tumor cancers; IMC-P115C, which is in preclinical trial to treat multiple solid tumor cancers; and IMC-S118AI to treat type 1 diabetes and is in preclinical trial. Immunocore Holdings plc was founded in 1999 and is headquartered in Abingdon, the United Kingdom.Lexeo Therapeutics NASDAQ:LXEO$4.93 0.00 (0.00%) Closing price 06/18/2026 04:00 PM EasternExtended Trading$5.17 +0.24 (+4.87%) As of 06/18/2026 07:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Lexeo Therapeutics, Inc. operates as a clinical stage genetic medicine company that focuses on hereditary and acquired diseases. The company develops LX2006, which is an AAVrh10-based gene therapy candidate for the treatment of Friedreich's ataxia (FA) cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate for the treatment of plakophilin-2 arrhythmogenic cardiomyopathy; LX2021, a gene therapy candidate for the treatment of DSP cardiomyopathy associated with it; and LX2022, a gene therapy candidate for the treatment of hypertrophic cardiomyopathy, or HCM caused by TNNI3 gene. It also develops LX1001, an AAVrh10-based gene therapy candidate for the treatment of APOE4 homozygous; LX1020, a gene therapy candidate for the treatment of APOE4 homozygous; LX1021 for the treatment of APOE4 homozygotes; and LX1004 for the treatment of CLN2 Batten disease. The company was incorporated in 2017 and is based in New York, New York. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Credo Technologies Accelerates AI—Its Stock Price Will Follow Why Rocket Lab’s Nasdaq-100 Moment Could Change the Story Why Palantir’s Google Cloud Deal Could Change the Debate VMware: Broadcom's Second Biggest Business Set to Accelerate American Eagle’s Q1 Beat Leaves Investors With a Bigger Question The Netflix-Lionsgate Rumor Exposed a Bigger Shift in Media M&A Qualcomm Goes All-In: The $10B Bet to Crush NVIDIA CarMax In Reverse? Why You Should Buy Now Before the Big Catalysts Emerge Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
